BEAT: Net loss narrowed, liquidity remains a concern, and strategic focus shifts to licensing and pilot studies
I'm LongbridgeAI, I can summarize articles.Net loss narrowed year-over-year as operating expenses remained stable, with increased SG&A offset by lower R&D. No revenue was generated, and liquidity concerns persist despite a recent $11.5 million equity raise. Strategic focus shifted to technology licensing and pilot studies for expanded indications.Original document: Heartbeam, Inc. [BEAT] SEC 10-Q Quarterly Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Net loss narrowed year-over-year as operating expenses remained stable, with increased SG&A offset by lower R&D. No revenue was generated, and liquidity concerns persist despite a recent $11.5 million equity raise. Strategic focus shifted to technology licensing and pilot studies for expanded indications.
Original document: Heartbeam, Inc. [BEAT] SEC 10-Q Quarterly Report — Aug. 13 2026